EVAX (Evaxion Biotech AS) Total Assets : $15.19 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Total Assets?

Evaxion Biotech AS's Total Assets for the quarter that ended in Sep. 2024 was $15.19 Mil.

During the past 12 months, Evaxion Biotech AS's average Total Assets Growth Rate was 13.60% per year. During the past 3 years, the average Total Assets Growth Rate was 6.00% per year. During the past 5 years, the average Total Assets Growth Rate was 53.90% per year.

During the past 7 years, Evaxion Biotech AS's highest 3-Year average Total Assets Growth Rate was 94.90%. The lowest was 6.00%. And the median was 57.40%.

Total Assets is connected with ROA %. Evaxion Biotech AS's annualized ROA % for the quarter that ended in Sep. 2024 was -50.89%. Total Assets is also linked to Revenue through Asset Turnover. Evaxion Biotech AS's Asset Turnover for the quarter that ended in Sep. 2024 was 0.20.

Evaxion Biotech AS Total Assets Historical Data

The historical data trend for Evaxion Biotech AS's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Total Assets Chart

Evaxion Biotech AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

11.08

11.97

40.16

22.03

12.89

Evaxion Biotech AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															11.94	12.89	22.65	15.23	15.19

Evaxion Biotech AS Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Evaxion Biotech AS's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-4.739	+	17.628
	=	12.89

Evaxion Biotech AS's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	0.074	+	15.185
	=	15.26

Evaxion Biotech AS (NAS:EVAX) Total Assets Explanation

Total Assets is connected with ROA %.

Evaxion Biotech AS's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-7.74	/	( (15.231	+	15.185)	/ 2 )
	=	-7.74	/	15.208
	=	-50.89 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Evaxion Biotech AS's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	3.017	/	( (15.231	+	15.185)	/ 2 )
=	3.017	/	15.208
=	0.20

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Evaxion Biotech AS Total Assets Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970

Website

https://www.evaxion-biotech.com

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.